Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889385 | 0.89 | MAPT (0.55) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL5257069 | 0.88 | MAPK1 (0.63) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL2972760 | 0.84 | RBP4 (0.52) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL4532938 | 0.79 | MET (0.50) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL4080008 | 0.78 | HMOX1 (0.49) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL2979198 | 0.78 | MAPK1 (0.78) | MAPK1BRD4CREBBP | |
| SCHEMBL4093739 | 0.77 | HMOX1 (0.50) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL5126874 | 0.77 | HMOX1 (0.52) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL4083458 | 0.75 | HMOX1 (0.51) | METMAPK1MAPK3MAP2K1FLT3 | |
| SCHEMBL4527352 | 0.74 | HMOX1 (0.51) | METMAPK1MAPK3MAP2K1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315490-B1 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1309593-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050245576-A1 | Substituted pyrazoles | BUTLER CHRISTOPHER R | 2005-11-03 | — | — | US | disclosed |
| US-6953793-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6583155-B2 | Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1315490-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309593-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245576-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MET 4506/4885MAPK1 4426/4885MAPK3 3267/4885 |
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MET 4506/4885MAPK1 4426/4885MAPK3 3267/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MET 3245/4885MAPK1 4370/4885MAPK3 2690/4885 |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MET 3245/4885MAPK1 4370/4885MAPK3 2690/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MET 3245/4885MAPK1 4370/4885MAPK3 2690/4885 |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | CTSS, CMA1, CTSZ | MET 3970/4885MAPK1 3828/4885MAPK3 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.